阿法替尼对比吉非替尼治疗EGFR突变阳性晚期非小细胞肺癌:IIb期LUX-Lung 7试验的总生存数据
LUX-Lung 7研究比较阿法替尼40mg/日与吉非替尼250mg/日一线治疗EGFR突变(19外显子缺失/L858R)IIIb/IV期非小细胞肺癌。中位随访42.6个月,两组总生存无显著差异(27.9 vs 24.5个月,HR=0.86,95%CI 0.66-1.12,P=0.2580)。阿法替尼更新的无进展生存(独立评审)、治疗失败时间和客观缓解率显著改善。
要点
- 阿法替尼与吉非替尼总生存无显著差异:中位27.9 vs 24.5个月,HR=0.86,95%CI 0.66-1.12,P=0.2580
- 19外显子缺失亚组中位总生存30.7 vs 26.4个月,HR=0.83,95%CI 0.58-1.17,P=0.2841
- L858R亚组中位总生存25.0 vs 21.2个月,HR=0.91,95%CI 0.62-1.36,P=0.6585
核心结论
- LUX-Lung 7研究中阿法替尼对比吉非替尼总生存无显著差异。
- 阿法替尼更新的无进展生存(独立评审)、治疗失败时间和客观缓解率数据显著改善。
研究设计与样本
- LUX-Lung 7为IIb期试验,评估阿法替尼40mg/日对比吉非替尼250mg/日用于初治IIIb/IV期非小细胞肺癌且携带常见EGFR突变(19外显子缺失/L858R)的患者。
- 主要总生存分析计划在约213例总生存事件且随访≥32个月后进行。
- 总生存采用Cox比例风险模型分析,按EGFR突变类型和基线脑转移分层。
主要发现
- 数据截止2016年4月8日时发生226例总生存事件;中位随访42.6个月后,阿法替尼对比吉非替尼中位总生存为27.9 vs 24.5个月(HR=0.86,95%CI 0.66-1.12,P=0.2580)。
- 预设亚组分析显示19外显子缺失患者中位总生存阿法替尼对比吉非替尼为30.7 vs 26.4个月(HR=0.83,95%CI 0.58-1.17,P=0.2841)。
- L858R突变患者中位总生存阿法替尼对比吉非替尼为25.0 vs 21.2个月(HR=0.91,95%CI 0.62-1.36,P=0.6585)。
- 停用阿法替尼/吉非替尼后,多数患者(阿法替尼72.6%;吉非替尼76.8%)接受至少一种后续全身抗肿瘤治疗;分别有20例(13.7%)和23例(15.2%)患者接受第三代EGFR酪氨酸激酶抑制剂。
关键数值与推荐
- 阿法替尼40mg/日对比吉非替尼250mg/日。
- 中位总生存阿法替尼27.9个月对比吉非替尼24.5个月(HR=0.86,95%CI 0.66-1.12,P=0.2580)。
- 19外显子缺失亚组中位总生存阿法替尼30.7个月对比吉非替尼26.4个月(HR=0.83,95%CI 0.58-1.17,P=0.2841)。
- L858R亚组中位总生存阿法替尼25.0个月对比吉非替尼21.2个月(HR=0.91,95%CI 0.62-1.36,P=0.6585)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. PATIENTS AND METHODS: LUX-Lung 7 assessed afatinib 40 mg/day versus gefitinib 250 mg/day in treatment-naïve patients with stage IIIb/IV NSCLC and a common EGFR mutation (exon 19 deletion/L858R). Primary OS analysis was planned after ∼213 OS events and ≥32-month follow-up. OS was analysed by a Cox proportional hazards model, stratified by EGFR mutation type and baseline brain metastases. RESULTS: Two-hundred and twenty-six OS events had occurred at the data cut-off (8 April 2016). After a median follow-up of 42.6 months, median OS (afatinib versus gefitinib) was 27.9 versus 24.5 months [hazard ratio (HR) = 0.86, 95% confidence interval (CI) 0.66‒1.12, P = 0.2580]. Prespecified subgroup analyses showed similar OS trends (afatinib versus gefitinib) in patients with exon 19 deletion (30.7 versus 26.4 months; HR, 0.83, 95% CI 0.58‒1.17, P = 0.2841) and L858R (25.0 versus 21.2 months; HR 0.91, 95% CI 0.62‒1.36, P = 0.6585) mutations. Most patients (afatinib, 72.6%; gefitinib, 76.8%) had at least one subsequent systemic anti-cancer treatment following discontinuation of afatinib/gefitinib; 20 (13.7%) and 23 (15.2%) patients received a third-generation EGFR tyrosine kinase inhibitor. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib. CONCLUSION: In LUX-Lung 7, there was no significant difference in OS with afatinib versus gefitinib. Updated PFS (independent review), TTF and ORR data were significantly improved with afatinib. CLINICALTRIALS.GOV IDENTIFIER: NCT01466660.
引用
- Paz-Ares L, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017. PMID: 28426106. doi:10.1093/annonc/mdw611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。